Journal of Neuro-Oncology

, Volume 52, Issue 3, pp 241–247 | Cite as

Characteristic Chromosomal Aberrations in Sporadic Cerebellar Hemangioblastomas Revealed by Comparative Genomic Hybridization

  • Sandra H.E. Sprenger
  • Johanna M.M. Gijtenbeek
  • Pieter Wesseling
  • Raf Sciot
  • Frank Van Calenbergh
  • Martin Lammens
  • Judith W. M. Jeuken


Hemangioblastomas (HBs) of the central nervous system are benign tumors and occur as sporadic (sp) tumors (75%) or as a manifestation of the von Hippel-Lindau (VHL) disease (25%). VHL-disease is an autosomal dominant disorder characterized by HBs of the central nervous system and retina, renal cell carcinoma (RCC), phaeochromocytoma (PHEO), islet tumors of the pancreas, and endolympatic sac tumors as well as cysts and cystadenoma in the kidney, pancreas and epididymis. In VHL patients a large spectrum of germline mutations in the VHL gene has been detected. In spHBs VHL alleles are reported to be inactivated in up to 50% of the tumors. To our knowledge the involvement of other genes in spHBs has not been investigated. To elucidate the oncogenesis of spHBs, we performed CGH on 10 spHBs to screen for chromosomal imbalances throughout the entire tumor genome. Aberrations most frequently detected are losses of chromosomes 3 (70%), 6 (50%), 9 (30%), and 18q (30%) and a gain of chromosome 19 (30%). Based on these frequencies and the co-occurrence of these aberrations in the analyzed tumors we hypothesize that loss of chromosome 3 (harboring the VHL gene) is an early event in the oncogenesis of spHBs, followed by loss of 6, and then losses of chromosomes 9, 18q and gain of chromosome 19. Comparison of the chromosomal imbalances in spHBs to those previously reported in RCCs and PHEOs reveals that the pathway of spHBs shows similarities to both the RCCs and PHEOs.

CGH chromosome 3 chromosome 6 hemangioblastomas oncogenesis sporadic 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burger PC, Scheithauer BW: Tumors of the central nervous system. In: Atlas of tumor pathology. Armed forces intitute of pathology, Washington, D.C., 1994Google Scholar
  2. 2.
    Kleiheus P, Cavenee WK: Pathology and genetics of tumours of the nervous system – World Health Organization classification of tumours, 1999Google Scholar
  3. 3.
    McKusick VA: Mendelian inheritance in man: a catalogue of human genes and genetic disorders. The John Hopkins University Press, Baltimore & London 11th issue, 1994Google Scholar
  4. 4.
    Latif F, Tory K, Gnarra JR, Yoa M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Schmidt MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–1320, 1993Google Scholar
  5. 5.
    Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Yao M: Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54: 4845–4847, 1994Google Scholar
  6. 6.
    Oberstrass J, Reifenberger G, Reifenberger J, Wechsler W, Collins VP: Mutations of the von Hippel-Lindau tumor suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 179: 151–156, 1996Google Scholar
  7. 7.
    Lee J, Dong S, Park W, Yoo N, Kim C, Jang J, Chi J, Zbar BLIA, Linehan WM, Vortmeyer AO, Zhuang Z: Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58: 504–508, 1998Google Scholar
  8. 8.
    Glaskar S, Bender BU, Apel TW, Natt E, van Velthoven V, Scheremet R, Zentner J, Neumann HPH: The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 67: 758–762, 1999Google Scholar
  9. 9.
    Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garret KP, et al.: Inhibition of transcription elongation by the VHL tumor suppresor protein. Science 269(5229): 1402–1406, 1995Google Scholar
  10. 10.
    Pause A, Peterson B, Schaffar G, Stearma R, Klausner RD: Studying interactions of four proteins in the yeast twohybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad SciUSA 96(17): 9533–9538, 1999Google Scholar
  11. 11.
    Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman FM, Pinkel D: Comparitive Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors. Science 258: 818–821, 1992Google Scholar
  12. 12.
    du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T: Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 90: 590–610, 1993Google Scholar
  13. 13.
    Presti JC, Moch H, Reuter VE, Cordon-Cardo C, Waldman F: Renal cell carcinoma genetic analysis by comparative genomic hybridization and restriction fragment length polymorphism analysis. J Urology 156: 281–285, 1996Google Scholar
  14. 14.
    Gronwald J, Strokel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, Lubinski J, Cremer T: Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: Importance of 1q and 3p copy number changes in metastatic events. Cancer Res 57: 481–487, 1997Google Scholar
  15. 15.
    Moch H, Presti JC, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, Waldman FM: Genetic aberration detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56: 27–30, 1996Google Scholar
  16. 16.
    Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, Goncharov N, Tean Teh B, Backdahl M, Larsson C: Comparative genomic hybridization reveals frequent losses of chromosome 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 156: 651–659, 2000Google Scholar
  17. 17.
    Jeuken JWM, Sprenger SHE, Wesseling P, Macville MVE, von Deimling A, Teepen HLJM, van Overbeeke JJ, Boerman RH: Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 58: 606–612, 1999Google Scholar
  18. 18.
    Miller SA, Dykes DD, Polsky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215, 1988Google Scholar
  19. 19.
    Schraml P, Zhaou M, Richter J, Brunning Th, Pommer M, Sauter G, Mihatsch MJ, Moch H: Analysis of Renal Tumors in Trichloroethylene-exposed Workers by Comparative Genomic Hybridisation and DNA Sequencing analysis. Verhandlungen der Deutschen Gesellschaft fur Pathologie 83: 218–224, 1999Google Scholar
  20. 20.
    Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rafai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkannen M, Varis A, Wasenius VM, Wolf M, Zhu Y: DNA copy number losses in human neoplasms. Am J Pathol 155: 683–694, 1999Google Scholar
  21. 21.
    Olschwang S, Richard S, Boisson C, Giraud S, Laurent-Puig P, Resche F, Thomas G: Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic heamangioblastoma. Human Mutation 12: 424–430, 1998Google Scholar
  22. 22.
    Tse JYM, Wong JHC, Lo K, Poon W, Huang D, Ng H: Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar haemangioblastomas. Am J Clin Pathol 107: 459–466, 1997Google Scholar
  23. 23.
    Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DR, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor suppressor gene by DNA methylation in renal cell carcinoma. Proc Natl Acad Sci USA 91: 9700–9704, 1995Google Scholar
  24. 24.
    Richard S, David P, Marsot-Dupuch K, Giraud S, Beroud C, Resche F: Central nervous system haemangioblastomas, endolympatic sac tumors, and von Hippel-Lindau disease. Springer-Verlag 23: 1–22, 2000Google Scholar
  25. 25.
    Stratmann R, Krieg M, Haas R, Plate KH: Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol Exp Neurol 56: 1242–1252, 2000Google Scholar
  26. 26.
    Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and 247 sporadic hemangioblastomas. Cancer Res 55: 1358–1364, 1995Google Scholar
  27. 27.
    Bohling T, Turunen O, Jaaskelainen J, Carpen O, Saino M, Wahlstrom T, Vaheri A, Haltia M: Ezrin expression in stromal cells of capillary hemangioblastoma. Am J Pathol 148: 367–373, 1996Google Scholar
  28. 28.
    Knuutila S, Bjorkqvist AM, Autio K, Trakkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rafai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y: DNA copy number amplifications in human neoplasms. Am J Pathol 152: 1107–1123, 1998Google Scholar
  29. 29.
    Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfoeld EH, Zhuang Z: von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 28: 541–543, 1997Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Sandra H.E. Sprenger
    • 1
  • Johanna M.M. Gijtenbeek
    • 1
  • Pieter Wesseling
    • 1
    • 2
  • Raf Sciot
    • 3
  • Frank Van Calenbergh
    • 4
  • Martin Lammens
    • 1
    • 3
  • Judith W. M. Jeuken
    • 1
  1. 1.Department of NeurologyUniversity Medical Center NijmegenNijmegenThe Netherlands
  2. 2.Department of PathologyUniversity Medical Center NijmegenNijmegenThe Netherlands
  3. 3.Department of PathologyUniversity Hospital K.ULeuvenBelgium
  4. 4.Department of NeurosurgeryUniversity Hospital K.ULeuvenBelgium

Personalised recommendations